Who Buys Ceftriaxone from India — 2555 Importers Behind a $285.4M Market

The 2,555 buyers of Ceftriaxone from India can be categorized into several segments:

1. Distributors: Entities like SAAM GROUP LTD in Pakistan and SEA GOLD PHARMA in Turkey function as intermediaries, purchasing large volumes to supply regional markets. Their buying behavior is characterized by bulk orders to achieve economies of scale, with a focus on maintaining consistent supply chains.

2. Government Procurement Agencies: Organizations such as PHARMACIE CENTRALE GUINEE in Guinea and TO THE DIRECTOR OF in Sudan are likely involved in national healthcare procurement. They typically engage in tender-based purchasing, emphasizing cost-effectiveness and compliance with national health policies.

3. Hospital Groups: Entities like ROYAL PHARMA 2011 LIMITED in Kenya and KHAN SEHAT LTD in Afghanistan may represent hospital networks or large healthcare providers. Their procurement patterns often involve regular, sizable orders to meet the consistent demand within healthcare facilities.

4. Retail Chains: Companies such as AUROVIDA FARMACEUTICA, SA DE CV in Mexico and EUGIA PHARMA INDUSTRIA FARMACEUTICA in Brazil likely operate extensive pharmacy networks. They procure Ceftriaxone to stock their outlets, ensuring availability for outpatient treatments, with purchasing patterns influenced by consumer demand and inventory turnover rates.

5. Re-exporters: Firms like AL JABAL DRUGS & MEDICAL APPLIANCES in Yemen may act as re-exporters, importing Ceftriaxone for redistribution to neighboring regions. Their buying behavior is driven by regional demand fluctuations and trade agreements.

6. Contract Manufacturers: Entities such as M/S. PRINCE PHARMA DEPOT PHARMACETI in the Democratic Republic of Congo might engage in contract manufacturing, importing raw Ceftriaxone for local formulation and packaging. Their procurement is typically aligned with production schedules and contractual obligations.

Kenya:

1. 1Drug Regulatory Authority: Pharmacy and Poisons Board (PPB).
2. 2Import Registration Process: Importers must register pharmaceutical products with the PPB, providing comprehensive documentation, including product dossiers and evidence of Good Manufacturing Practice (GMP) compliance.
3. 3Estimated Timeline for Registration: Approximately 6 to 12 months, depending on the completeness of the application and regulatory reviews.
4. 4Import Tariff/Duty for HS 30042019: Pharmaceutical products under this HS code are typically exempt from import duties, aligning with Kenya's commitment to affordable healthcare.

Afghanistan:

1. 1Drug Regulatory Authority: Afghanistan National Medicines and Health Products Regulatory Authority (ANMHRA).
2. 2Import Registration Process: Requires submission of product dossiers, GMP certificates, and samples for quality assessment.
3. 3Estimated Timeline for Registration: Approximately 9 to 15 months, subject to regulatory capacity and security conditions.
4. 4Import Tariff/Duty for HS 30042019: Pharmaceutical imports are generally subject to a 2% customs duty, with potential exemptions for essential medicines.

Mexico:

1. 1Drug Regulatory Authority: Federal Commission for the Protection against Sanitary Risk (COFEPRIS).
2. 2Import Registration Process: Involves submission of detailed product information, clinical data, and compliance with Mexican Official Standards (NOMs).
3. 3Estimated Timeline for Registration: Approximately 12 to 18 months, depending on the product's complexity and regulatory workload.
4. 4Import Tariff/Duty for HS 30042019: Pharmaceutical products are generally exempt from import duties, promoting access to essential medicines.

Guinea:

1. 1Drug Regulatory Authority: National Directorate of Pharmacy and Medicine (DNPM).
2. 2Import Registration Process: Requires submission of product dossiers, GMP certificates, and samples for evaluation.
3. 3Estimated Timeline for Registration: Approximately 8 to 12 months, contingent on regulatory efficiency and resource availability.
4. 4Import Tariff/Duty for HS 30042019: Essential medicines are typically exempt from import duties to facilitate healthcare access.

Ethiopia:

1. 1Drug Regulatory Authority: Ethiopian Food and Drug Authority (EFDA).
2. 2Import Registration Process: Involves submission of comprehensive product dossiers, GMP certificates, and adherence to national standards.
3. 3Estimated Timeline for Registration: Approximately 12 to 24 months, influenced by regulatory capacity and process efficiency.
4. 4Import Tariff/Duty for HS 30042019: Pharmaceutical imports are generally exempt from import duties, supporting the availability of essential medicines.

The demand for Ceftriaxone in importing countries is driven by several factors:

1. Disease Prevalence: High incidences of bacterial infections such as pneumonia, meningitis, and typhoid fever necessitate the use of broad-spectrum antibiotics like Ceftriaxone. For instance, a study in Ethiopia highlighted inappropriate Ceftriaxone use for conditions like typhoid fever and pneumonia, indicating its widespread application in treating these diseases.

2. Government Healthcare Programs: Many countries have national health initiatives aimed at combating infectious diseases, leading to bulk procurement of essential antibiotics.

3. Universal Health Coverage Expansion: Efforts to achieve universal health coverage increase the accessibility of essential medicines, boosting demand for antibiotics.

4. WHO Essential Medicines List Procurement: Ceftriaxone's inclusion in the WHO Model List of Essential Medicines underscores its critical role in healthcare, prompting countries to prioritize its procurement.

5. Tender-Based Purchasing: Many governments and international organizations utilize tendering processes to procure medicines, ensuring competitive pricing and consistent supply.

With 2,555 buyers across 162 countries, the global market for Ceftriaxone presents substantial opportunities. Understanding the specific demand drivers and regulatory landscapes in each importing country is crucial for strategic market engagement and sustained growth.

The 2,555 buyers of Ceftriaxone from India can be categorized into several segments:

1. Distributors: Entities like SAAM GROUP LTD in Pakistan and SEA GOLD PHARMA in Turkey function as intermediaries, purchasing large volumes to supply regional markets. Their buying behavior is characterized by bulk orders to achieve economies of scale, with a focus on maintaining consistent supply chains.

2. Government Procurement Agencies: Organizations such as PHARMACIE CENTRALE GUINEE in Guinea and TO THE DIRECTOR OF in Sudan are likely involved in national healthcare procurement. They typically engage in tender-based purchasing, emphasizing cost-effectiveness and compliance with national health policies.

3. Hospital Groups: Entities like ROYAL PHARMA 2011 LIMITED in Kenya and KHAN SEHAT LTD in Afghanistan may represent hospital networks or large healthcare providers. Their procurement patterns often involve regular, sizable orders to meet the consistent demand within healthcare facilities.

4. Retail Chains: Companies such as AUROVIDA FARMACEUTICA, SA DE CV in Mexico and EUGIA PHARMA INDUSTRIA FARMACEUTICA in Brazil likely operate extensive pharmacy networks. They procure Ceftriaxone to stock their outlets, ensuring availability for outpatient treatments, with purchasing patterns influenced by consumer demand and inventory turnover rates.

5. Re-exporters: Firms like AL JABAL DRUGS & MEDICAL APPLIANCES in Yemen may act as re-exporters, importing Ceftriaxone for redistribution to neighboring regions. Their buying behavior is driven by regional demand fluctuations and trade agreements.

6. Contract Manufacturers: Entities such as M/S. PRINCE PHARMA DEPOT PHARMACETI in the Democratic Republic of Congo might engage in contract manufacturing, importing raw Ceftriaxone for local formulation and packaging. Their procurement is typically aligned with production schedules and contractual obligations.

Kenya:

1. 1Drug Regulatory Authority: Pharmacy and Poisons Board (PPB).
2. 2Import Registration Process: Importers must register pharmaceutical products with the PPB, providing comprehensive documentation, including product dossiers and evidence of Good Manufacturing Practice (GMP) compliance.
3. 3Estimated Timeline for Registration: Approximately 6 to 12 months, depending on the completeness of the application and regulatory reviews.
4. 4Import Tariff/Duty for HS 30042019: Pharmaceutical products under this HS code are typically exempt from import duties, aligning with Kenya's commitment to affordable healthcare.

Afghanistan:

1. 1Drug Regulatory Authority: Afghanistan National Medicines and Health Products Regulatory Authority (ANMHRA).
2. 2Import Registration Process: Requires submission of product dossiers, GMP certificates, and samples for quality assessment.
3. 3Estimated Timeline for Registration: Approximately 9 to 15 months, subject to regulatory capacity and security conditions.
4. 4Import Tariff/Duty for HS 30042019: Pharmaceutical imports are generally subject to a 2% customs duty, with potential exemptions for essential medicines.

Mexico:

1. 1Drug Regulatory Authority: Federal Commission for the Protection against Sanitary Risk (COFEPRIS).
2. 2Import Registration Process: Involves submission of detailed product information, clinical data, and compliance with Mexican Official Standards (NOMs).
3. 3Estimated Timeline for Registration: Approximately 12 to 18 months, depending on the product's complexity and regulatory workload.
4. 4Import Tariff/Duty for HS 30042019: Pharmaceutical products are generally exempt from import duties, promoting access to essential medicines.

Guinea:

1. 1Drug Regulatory Authority: National Directorate of Pharmacy and Medicine (DNPM).
2. 2Import Registration Process: Requires submission of product dossiers, GMP certificates, and samples for evaluation.
3. 3Estimated Timeline for Registration: Approximately 8 to 12 months, contingent on regulatory efficiency and resource availability.
4. 4Import Tariff/Duty for HS 30042019: Essential medicines are typically exempt from import duties to facilitate healthcare access.

Ethiopia:

1. 1Drug Regulatory Authority: Ethiopian Food and Drug Authority (EFDA).
2. 2Import Registration Process: Involves submission of comprehensive product dossiers, GMP certificates, and adherence to national standards.
3. 3Estimated Timeline for Registration: Approximately 12 to 24 months, influenced by regulatory capacity and process efficiency.
4. 4Import Tariff/Duty for HS 30042019: Pharmaceutical imports are generally exempt from import duties, supporting the availability of essential medicines.

The demand for Ceftriaxone in importing countries is driven by several factors:

1. Disease Prevalence: High incidences of bacterial infections such as pneumonia, meningitis, and typhoid fever necessitate the use of broad-spectrum antibiotics like Ceftriaxone. For instance, a study in Ethiopia highlighted inappropriate Ceftriaxone use for conditions like typhoid fever and pneumonia, indicating its widespread application in treating these diseases.

2. Government Healthcare Programs: Many countries have national health initiatives aimed at combating infectious diseases, leading to bulk procurement of essential antibiotics.

3. Universal Health Coverage Expansion: Efforts to achieve universal health coverage increase the accessibility of essential medicines, boosting demand for antibiotics.

4. WHO Essential Medicines List Procurement: Ceftriaxone's inclusion in the WHO Model List of Essential Medicines underscores its critical role in healthcare, prompting countries to prioritize its procurement.

5. Tender-Based Purchasing: Many governments and international organizations utilize tendering processes to procure medicines, ensuring competitive pricing and consistent supply.

With 2,555 buyers across 162 countries, the global market for Ceftriaxone presents substantial opportunities. Understanding the specific demand drivers and regulatory landscapes in each importing country is crucial for strategic market engagement and sustained growth.